---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-357380"
form_type: "8-K"
ticker: "LLY"
cik: "0000059478"
company_name: "ELI LILLY & Co"
filed_at: "2021-12-15T23:59:59+00:00"
generated_at: "2026-06-28T01:03:48.880344+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lilly raises 2021 revenue guidance to $28.0B-$28.3B; 2022 EPS seen at $8.00-$8.15

## Summary
- 2021 revenue guidance raised to $28.0B-$28.3B (from $27.2B-$27.6B); non-GAAP EPS raised to $8.15-$8.20.
- 2022 revenue guidance $27.8B-$28.3B; reported EPS $8.00-$8.15; non-GAAP EPS $8.50-$8.65.
- Initiated rolling FDA submission for pirtobrutinib in MCL; completion in 2022, regulatory action early 2023.
- Plans new phase 3 studies for tirzepatide in obesity outcomes, sleep apnea, and kidney disease; donanemab biomarker data disclosed.

## SEC filing metadata
- accession: 0001193125-21-357380
- form_type: 8-K
- ticker: LLY
- cik: 0000059478
- company_name: ELI LILLY & Co
- filed_at: 2021-12-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/59478/000119312521357380/0001193125-21-357380-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/59478/000119312521357380/d212746d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-357380
- JSON: https://secwatch.observer/filing/0001193125-21-357380.json
- Plain text: https://secwatch.observer/filing/0001193125-21-357380.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.